Differential Stimulation of Insulin Secretion by GLP 1 | you won't want to miss

By Charles

Differential Stimulation of Insulin Secretion by GLP

PDF Differential Stimulation of Insulin Secretion by GLP 1
PDF Differential Stimulation of Insulin Secretion by GLP 1

These data suggest that KP likely alters insulin secretion through a G βγ -dependent process that stimulates glucose metabolism without altering Ca 2+ activity, while GLP-1 does so, at least partly, through a G α -dependent pathway that is independent of both metabolism and Ca 2+.

The role of amylin and incretin hormones GLP 1 and GIP in maintaining
The role of amylin and incretin hormones GLP 1 and GIP in maintaining

Despite many studies, the signaling mechanisms by which KP and GLP-1 potentiate insulin release are not thoroughly understood. We investigated the downstream signaling pathways of these ligands and their affects on cellular redox potential, intracellular calcium activity ( [Ca2+]i), and insulin secretion from β-cells within intact murine islets.

Differential stimulation of insulin secretion by GLP

The biology of incretin hormones Cell Metabolism
The biology of incretin hormones Cell Metabolism

Despite many studies, the signaling mechanisms by which KP and GLP-1 potentiate insulin release are not thoroughly understood. We investigated the downstream signaling pathways of these ligands and their affects on cellular redox potential, intracellular calcium activity ( [Ca (2+)]i), and insulin secretion from β-cells within intact murine ...

These data suggest that KP likely alters insulin secretion through a Gbc-dependent process that stimulates glucose metabolism without altering Ca2+ activity, while GLP-1 does so, at least partly, through a Ga-dependent pathway that is independent of both metabolism and Ca2+.

Mechanism of Action of GLP 1
Mechanism of Action of GLP 1

(PDF) Differential Stimulation of Insulin Secretion by GLP

These data suggest that KP likely alters insulin secretion through a Gβγ-dependent process that stimulates glucose metabolism without altering Ca2+ activity, while GLP-1 does so, at least partly ...

Abstract Stimulation of insulin secretion by glucagon-like peptide-1 ( GLP-1 ) and other gut-derived peptides is central to the incretin response to ingesting nutriments. Analogues of GLP-1 , and inhibitors of its breakdown, have found widespread clinical use for the treatment of type 2 diabetes (T2D) and obesity.

Frontiers
Frontiers

Overview of Differential Stimulation Of Insulin Secretion By Glp 1

GLP-1 and its analogs enhance insulin secretion , but the specific intracellular mechanisms in β-cells remain unclear. Key intracellular mediators including calcium, glutamate, γ-aminobutyric acid, serotonin, and urocortin-3 are modulated by GLP-1 signaling with variable and sometimes contradictory effects.

Both GLP-1 and glucose participated in regulating every single step of the secretion pathway, and systematically synergized their effects in inducing insulin secretion .

A new concept for intracellular signaling pathway of glucagon like
A new concept for intracellular signaling pathway of glucagon like

Systematic Synergy of Glucose and GLP

Finally, we found glucose and GLP-1 executed their synergistic effect at multiple levels, especially at pathway level. Both GLP-1 and glucose participated in regulating every single step of the secretion pathway, and systematically synergized their effects in inducing insulin secretion .

PDF The Multiple Actions of GLP 1 on the Process of Glucose
PDF The Multiple Actions of GLP 1 on the Process of Glucose
GLP 1 stimulated insulin release
GLP 1 stimulated insulin release
Mechanisms of first phase of insulin secretion by GLP 1 mimetics GLP 1
Mechanisms of first phase of insulin secretion by GLP 1 mimetics GLP 1
Frontiers
Frontiers
Diagram Showing Glp1 Receptor Pathway With Glucose Insulin And Gene
Diagram Showing Glp1 Receptor Pathway With Glucose Insulin And Gene
Bachem research focuses on GLP 1 treatment for diabetes
Bachem research focuses on GLP 1 treatment for diabetes
Incretin based therapy of type 2 diabetes mellitus 1
Incretin based therapy of type 2 diabetes mellitus 1

Lindquist et al. show that GLP-1 and semaglutide, but not exendin 4 or GIP, selectively drive GLP -1R-GIPR heterodimerization, altering receptor trafficking and signaling. These findings uncover a mechanistic basis for incretin crosstalk and provide a structural framework for optimizing therapies for obesity and type 2 diabetes.